




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

July 3, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
July 3, 2002	
Date	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 09/989,695 entitled "LIPOSOMAL IMEXON" by Gabriel Lopez-Berestein et al.*
Client Reference: MDA00-024
Our Reference: UTSC:648US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1, B1-B6, C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111317/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted

25182475.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gabriel Lopez-Berestein *et al.*

Serial No.: 09/989,695

Filed: November 20, 2001

For: LIPOSOMAL IMEXON

Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: UTSC:648US

RECEIVED
JUL 09 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
July 3, 2002	
Date	
	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111317/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 3, 2002

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:648USSerial No.
09/989,695

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Gabriel Lopez-Berestein *et al.*Filing Date:
November 20, 2001Group:
1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,083,987	4/11/78	Bicker <i>et al.</i>	424	273	5/26/76

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	2,644,820	4/6/78	Germany			No
	B2	2,656,323	6/15/78	Germany			No
	B3	2,727,550	1/4/79	Germany			Yes
	B4	2,740,248	3/15/79	Germany			No
	B5	WO 95/31545	11/23/95	PCT			
	B6	WO 99/00120	1/7/99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Bicker and Fuhse, "Carcinostatic action of 2-cyanaziridines against a sarcoma in rats," <i>Exp Pathol (Jena)</i> , 10(5-6):279-284, 1975.
	C2	Bicker, "Immunopharmacological properties of 2-cyanaziridine derivatives," <i>In Immune Modulation Agents and Their Mechanisms</i> , Fenical and Chirigos (Eds.), Marcel Dekker, New York and Basle, 447-473, 1984.
	C3	Bicker, "Biochemical and pharmacological properties of some new 2-cyanaziridines," <i>Fortschritte Der Medizin</i> , 96(12):661-664, 1978, Article in German with an English Summary.
	C4	Bicker and Hebold, "Cancerostatic action of the immune stimulating compound 4-imino-1,3-diazabicyclo[3.1.0]hexane-2-one, BM 06 002 (Proposed INN Name Imexon) on various transplantation tumors," <i>IRCS Med Sci. Cancer Hematol. Immunol. Allergy Pharmacol.</i> , 5:428, 1977.

25109163.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)
List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:648US

Serial No.

09/989,695

Applicant

Gabriel Lopez-Berestein *et al.*

Filing Date:

November 20, 2001

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Gutiérrez-Puente <i>et al.</i> , "Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2," <i>J. Pharmacology and Exp. Therapeutics</i> , 291(2):865-869, 1999.
	C6	Hersh <i>et al.</i> , "Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells <i>in vitro</i> ," <i>J. Natl. Cancer Inst.</i> , 84:1238-1244, 1992.
	C7	Hersh <i>et al.</i> , "Antitumor effects of the 2-cyanoaziridine imexon (IM) combined with myelosuppressive and non-myelosuppressive anticancer agents," <i>Proc. Am. Assoc. Cancer Res.</i> , 36:294, Abstract #1751, 1995.
	C8	Iyengar <i>et al.</i> , "Novel Antitumor 2-cyanoaziridine-1 carboxamides," <i>J. Med. Chem.</i> , 42:510-514, 1999
	C9	Jähnich <i>et al.</i> , "Chemie von Aziridinecarbonsäuren; 2. Mitteilung Eine Einfache Synthese von 2-Aminopropennitril," (Chemistry of Aziridinecarboxylic Acids; 2, Note on a Simple Synthesis of 2-Amino ropenenitrile)," <i>Synthesis</i> , 1211-1212, 1992, includes an English abstract.
	C10	Matsuoka <i>et al.</i> , "Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma," <i>Proc. Soc. Exp. Biol. Med.</i> , 125(4):1246-1250, 1967.
	C11	Micksche <i>et al.</i> , "Phase I study for a new immunostimulant drug," BM 06 002, <i>In Immune Modulation and Control of Neoplasia by Adjuvant Therapy</i> , Chirigos (Ed.), Raven Press, New York, 403-413, 1978.
	C12	Remers and Iyengar, "Antitumor Antibiotics—Mitomycins," <i>In Cancer Chemotherapeutic Agent</i> , Foye (Ed.), American Chemical Society, Washington, DC, 584-592, 1995.
	C13	Sagaster <i>et al.</i> , "Antitumor activity of imexon," <i>J. Natl. Cancer Inst.</i> , 87(12):935-936, 1995.
	C14	Salmon and Hersh, "Sensitivity of multiple myeloma to imexon in the human tumor cloning assay," <i>J. Natl. Cancer Inst.</i> , 86(3):228-230, 1994.

25109163.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)